Latest News for IDRSF
Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place from February 2-6, 2026.
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd (SIX: IDIA) announces an exclusive license and supply agreement with EMS S.A.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for IDRSF.
Senate Trading
No Senate trades found for IDRSF.
U.S. House Trading
No House trades found for IDRSF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.